Florbetaben PET Imaging in PPA

Florbetaben PET Imaging in Primary Progressive Aphasia

Status

Completed

Phases

Unknown

Study type

Observational

Source

ClinicalTrials.gov

Registry ID

NCT04720001

Enrollment

Registered

2021-01-22

Start date

2018-08-23

Completion date

2021-02-26

Last updated

2024-10-16

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Alzheimer Disease, Primary Progressive Aphasia

Keywords

Alzheimer's Disease, Dementia, Primary Progressive Aphasia, Neurocognitive Disorders, Speech Disorders

Brief summary

The purpose of this research is to better understand how dementia affects activity in different parts of the brain.

Detailed description

This study will examine Positron Emission Tomography (PET) imaging with Florbetaben F18. Florbetaben F18 is a radioactive tracer that binds to particles in your brain. This process displays activity in the brain. Florbetaben F18 is a PET amyloid imaging agent approved by the United States Food and Drug Administration (FDA) to estimate the amount of beta-amyloid plaque in adult patients who are being evaluated for Alzheimer's disease and other causes of cognitive decline. The purpose of this research is to better understand how dementia affects activity in different parts of the brain. Currently, the scientific community is limited by how well it can see inside the brain. The use of a PET scan better helps us understand what the brain looks like in a diseased state. Participation in the study will help to understand what brain activity looks like, especially around language regions.

Interventions

DRUGFlorbetaben F18

A single injection of 8.1mCi of florbetaben F18 will be administered by intravenous bolus injection

DEVICEPET

PET Scan for brain imaging

Study design

Observational model

CASE_ONLY

Time perspective

PROSPECTIVE

Eligibility

Sex/Gender

ALL

Age

18 Years to 100 Years

Healthy volunteers

Inclusion criteria

* Participants must have a diagnosis of PPA or a related dementia syndrome

Exclusion criteria

* Pregnant * Breastfeeding * Receiving radiation clinically

Design outcomes

Primary

Measure	Time frame	Description
Amyloid plaque levels in PPA participants	2 Years	Amyloid plaque aggregation as measured by florbetaben F18 standard uptake value ratio cerebral and cerebellar regions of interest.

Countries

United States

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026